MedTrace Logo

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

NCT03846310 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2024-12-09

No results posted yet for this study

Summary

This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).

Conditions

  • Non Small Cell Lung Cancer Metastatic
  • Non Small Cell Lung Cancer
  • Nonsquamous Nonsmall Cell Neoplasm of Lung
  • Sensitizing EGFR Gene Mutation

Interventions

DRUG

Etrumadenant

Etrumadenant is an A2aR and A2bR antagonist

DRUG

Zimberelimab

Zimberelimab is a fully human anti-PD-1 monoclonal antibody

DRUG

Carboplatin

Carboplatin administered as part of standard chemotherapy regimen

DRUG

Pemetrexed

Pemetrexed administered as part of standard chemotherapy regimen

DRUG

Pembrolizumab

Pembrolizumab is a humanized anti-PD-1 monoclonal antibody

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Arcus Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Arcus Biosciences, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2024-11-18
Completion
2024-11-18
FDA Drug
Yes

Countries

  • United States
  • Singapore
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03846310 on ClinicalTrials.gov